Dissecting the pro-neurogenic effects of monoaminergic medications used to treat depression: a systematic review and meta-analysis
Abstract
The neurogenic theory of depression proposes that chronic medications modulating monoaminergic neurotransmission may ameliorate symptoms of mood disorders by correcting stressor-induced disruptions in adult hippocampal neurogenesis. However, some controversial findings challenge this assertion. A systematic review and meta-analysis of all pertinent studies, corrected by publication bias, estimated a small, significant, and consistent pro-neurogenic effect of monoaminergic treatments in laboratory rodents. Nearly 30% of the literature exhibited low and 70% unclear risk of bias. In both naïve and stressed mice, pro-neurogenic effects occurred irrespective of strain, sex, stress, or behavioral testing experience. In rats, the effects were predominantly inconclusive due to the lower number of studies in this species. The available number of studies was also insufficient to yield definitive evidence for compounds acting as selective serotonin reuptake inhibitors (citalopram, escitalopram, fluvoxamine), serotonin-norepinephrine reuptake inhibitors (desvenlafaxine, duloxetine, venlafaxine), multimodal monoaminergic modulators (imipramine, desipramine), melatonergic compound (agomelatine), or norepinephrine-serotonin disinhibitory (mirtazapine). Subsequent updates of these reviews appear necessary to establish robust evidence regarding these compounds. Evidence was firm in favor of a robust pro-neurogenic effect of selective serotonin reuptake inhibitor fluoxetine, in both species, making updates of this review probably redundant.
Related
- A systematic fluorescently tagged protein toolkit for dissecting apical extracellular matrix patterning in C. elegans
- The Impact of Common Medications on Male Fertility: An Updated Systematic Review
- Associations of glucose- and lipid-lowering medications with incident or first-recorded psoriasis: a systematic review of real-world observational studies
- Monoaminergic changes are associated with impaired neurogenesis along the longitudinal axis of the hippocampus in ageing and dementia
- From promiscuity to specialization: The origin of cholinergic and monoaminergic signaling is pre-bilaterian
BibTeX
@article{bolzan2026dissecting,
title = {{Dissecting the pro-neurogenic effects of monoaminergic medications used to treat depression: a systematic review and meta-analysis}},
author = {Juliana A Bolzan and Tamires Martins and Karolina Domingues and Alexandre Surget and Catherine Belzung and Cilene Lino de Oliveira},
journal = {Journal of Psychopharmacology},
year = {2026},
month = oct,
doi = {10.1177/02698811251337382},
url = {https://hal.science/hal-05796322v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Dissecting the pro-neurogenic effects of monoaminergic medications used to treat depression: a systematic review and meta-analysis
AU - Juliana A Bolzan
AU - Tamires Martins
AU - Karolina Domingues
AU - Alexandre Surget
AU - Catherine Belzung
AU - Cilene Lino de Oliveira
PY - 2026
DA - 2026/10/13
JO - Journal of Psychopharmacology
DO - 10.1177/02698811251337382
UR - https://hal.science/hal-05796322v1
AB - The neurogenic theory of depression proposes that chronic medications modulating monoaminergic neurotransmission may ameliorate symptoms of mood disorders by correcting stressor-induced disruptions in adult hippocampal neurogenesis. However, some controversial findings challenge this assertion. A systematic review and meta-analysis of all pertinent studies, corrected by publication bias, estimated a small, significant, and consistent pro-neurogenic effect of monoaminergic treatments in laboratory rodents. Nearly 30% of the literature exhibited low and 70% unclear risk of bias. In both naïve and stressed mice, pro-neurogenic effects occurred irrespective of strain, sex, stress, or behavioral testing experience. In rats, the effects were predominantly inconclusive due to the lower number of studies in this species. The available number of studies was also insufficient to yield definitive evidence for compounds acting as selective serotonin reuptake inhibitors (citalopram, escitalopram, fluvoxamine), serotonin-norepinephrine reuptake inhibitors (desvenlafaxine, duloxetine, venlafaxine), multimodal monoaminergic modulators (imipramine, desipramine), melatonergic compound (agomelatine), or norepinephrine-serotonin disinhibitory (mirtazapine). Subsequent updates of these reviews appear necessary to establish robust evidence regarding these compounds. Evidence was firm in favor of a robust pro-neurogenic effect of selective serotonin reuptake inhibitor fluoxetine, in both species, making updates of this review probably redundant.
SN - 0269-8811
SN - 1461-7285
ER -